Total Post Count: 8 of 8

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Published by La Merie Business Intelligence
July 1, 2022
PDF
263
$2,000.00

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Published by La Merie Business Intelligence
July 1, 2022
PDF
66
$670.00

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

Published by La Merie Business Intelligence
June 1, 2022
PDF
115
$1,170.00

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Published by La Merie Business Intelligence
May 1, 2022
PDF
32
$450.00

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Published by La Merie Business Intelligence
May 1, 2022
PDF
50
$560.00

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Published by La Merie Business Intelligence
March 1, 2022
PDF
553
$2,700.00

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Published by La Merie Business Intelligence
October 1, 2021
PDF
433
$2,600.00

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

Published by La Merie Business Intelligence
July 1, 2021
PDF
259
$2,250.00